Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Mismatch Repair Protein Deficiency”

9 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 9 of 9 results

Not applicableStudy completedNCT03047226
What this trial is testing

Diagnosis of Lynch Syndrome Based on Next-generation Sequencing in Colorectal Cancer

Who this might be right for
Lynch Syndrome
Second Affiliated Hospital, School of Medicine, Zhejiang University 311
Testing effectiveness (Phase 2)Active Not RecruitingNCT03257163
What this trial is testing

Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer

Who this might be right for
Epstein-Barr Virus PositiveGastric AdenocarcinomaMismatch Repair Protein Deficiency+8 more
Rutgers, The State University of New Jersey 40
Early research (Phase 1)Study completedNCT03894618
What this trial is testing

SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

Who this might be right for
Squamous Cell Carcinoma of the Head and NeckMelanomaNon Small Cell Lung Cancer+10 more
Shattuck Labs, Inc. 49
Testing effectiveness (Phase 2)WithdrawnNCT06400264
What this trial is testing

Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory Lymphoma+2 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Study completedNCT04439214
What this trial is testing

Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 47
Large-scale testing (Phase 3)Ended earlyNCT06321068
What this trial is testing

BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer

Who this might be right for
Endometrial Cancer
Bio-Thera Solutions 5
Testing effectiveness (Phase 2)Active Not RecruitingNCT04556253
What this trial is testing

AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer

Who this might be right for
MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer
Peking University 47
Early research (Phase 1)Ended earlyNCT04458259
What this trial is testing

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

Who this might be right for
Neoplasm Metastasis
Pfizer 88
Testing effectiveness (Phase 2)Looking for participantsNCT06529523
What this trial is testing

Tislelizumab in People With Colorectal Cancer

Who this might be right for
Colorectal Cancer
Memorial Sloan Kettering Cancer Center 40